Ventas Inc. (NYSE:VTR) has significantly restructured its portfolio in the last two years to address a downturn in operational performance. And (despite a slew of analyst upgrades last week following Ventas's Investor Day, and news of a new Colony Capital (NYSE:CLNY) refinancing deal) the adverse impacts of these changes are expected to continue through 2019, at least. This article analyzes the various challenges that have brought Ventas to its current position and then considers the health of the business, valuation, risks, dividend safety, and concludes with our opinion about whether Ventas is an attractive choice for investors seeking stable long-term returns.
Ventas, Inc., an S&P 500 company, is a real estate investment trust ("REIT") with a diverse portfolio of approximately 1,200 assets in the United States, Canada and the United Kingdom. Its portfolio consists of seniors housing communities, medical office buildings, university-based research and innovation centers, inpatient rehabilitation and long-term acute care facilities, and health systems. Through its Lillibridge subsidiary, the company provides management, leasing, marketing, facility development and advisory services to highly rated hospitals and health systems throughout the United States.